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Elimination of Falciparum Malaria
and Emergence of Severe Dengue:
An Independent or Interdependent
Phenomenon?
Ib C. Bygbjerg1* , Lone Simonsen2 and Karin L. Schiøler1
1 Department of Public Health, University of Copenhagen, Copenhagen, Denmark, 2 Department of Science and
Environment, Roskilde University, Roskilde, Denmark
The global malaria burden, including falciparum malaria, has been reduced by 50% since
2000, though less so in Sub-Saharan Africa. Regional malaria elimination campaigns
beginning in the 1940s, up-scaled in the 1950s, succeeded in the 1970s in eliminating
malaria from Europe, North America, the Caribbean (except Haiti), and parts of Asia and
South- and Central America. Dengue has grown dramatically throughout the pantropical
regions since the 1950s, first in Southeast Asia in the form of large-scale epidemics
including severe dengue, though mostly sparing Sub-Saharan Africa. Globally, the
WHO estimates 50 million dengue infections every year, while others estimate almost
400 million infections, including 100 million clinical cases. Curiously, despite wide
geographic overlap between malaria and dengue-endemic areas, published reports of
co-infections have been scarce until recently. Superimposed acute dengue infection
might be expected to result in more severe combined disease because both pathogens
can induce shock and hemorrhage. However, a recent review found no reports on
more severe morbidity or higher mortality associated with co-infections. Cases of
severe dual infections have almost exclusively been reported from South America, and
predominantly in persons infected by Plasmodium vivax. We hypothesize that malaria
infection may partially protect against dengue – in particular falciparum malaria against
severe dengue – and that this inter-species cross-protection may explain the near
absence of severe dengue from the Sub-Saharan region and parts of South Asia
until recently. We speculate that malaria infection elicits cross-reactive antibodies or
other immune responses that infer cross-protection, or at least partial cross-protection,
against symptomatic and severe dengue. Plasmodia have been shown to give rise
to polyclonal B-cell activation and to heterophilic antibodies, while some anti-dengue
IgM tests have high degree of cross-reactivity with sera from malaria patients. In the
following, the historical evolution of falciparum malaria and dengue is briefly reviewed,
and we explore early evidence of subclinical dengue in high-transmission malaria areas
as well as conflicting reports on severity of co-morbidity. We also discuss examples of
other interspecies interactions.
Keywords: dengue, falciparum malaria, co-morbidity, cross-protection, heterologous immunity, interaction
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PRESENT AND PAST PREVALENCE OF
MALARIA, DENGUE, AND
POPULATION-LEVEL PROTECTION
AGAINST EACH DISEASE
Origin, Spread, and Burden of
Falciparum Malaria
Plasmodium falciparum malaria parasites probably emerged as
a human pathogen from its enzootic origin in West Africa
about 5,000–10,000 years ago (Carter and Mendis, 2002). This
coincides with the point in time when humans began living
in large agricultural communities, and when African Anopheles
mosquitoes adapted to the novel agrarian environment breeding
in man-made water collections and feeding almost exclusively on
humans. The parasite accompanied man to Asia and Melanesia
around 4,000 years ago and to the Americas with the slave trade
500 years ago (Curtin, 1993).
According to Carter and Mendis (2002), malaria reached
its apex during the 19th century, when more than half of the
global population was at risk of infection, and case fatality
rates reached above 10%. Declines in malaria incidence were
noted by the turn of the 20th century. The halving of the
global malaria mortality burden since 2000 has been attributed
to a combination of malaria interventions such as the use of
insecticide-treated nets (Beiersmann et al., 2011; Kramer et al.,
2017), indoor residual spraying, and artemisinin combination
therapy (Streatfield et al., 2014), as well as the effect of
development, such as increasing urbanization (Tatem et al., 2013)
and poverty reduction (Teklehaimanot and Mejia, 2008). Still,
each year more than 200 million cases and almost 0.5 million
deaths occur due to malaria; these deaths are mainly in children
in Sub-Saharan Africa and largely from Plasmodium falciparum
transmitted by nocturnal Anopheles species (Streatfield et al.,
2014). Transmission in urban areas is generally of lower intensity
than in rural areas but can be surprisingly elevated in some urban
environments (Wilson et al., 2015).
No effective vaccine exists for malaria, and natural immunity
takes years of repeated exposure to develop. Residents of
malaria-endemic areas eventually develop some immunity to
the infection (Tomson, 1933), but immunity wanes after a
single year without exposure (Hoffman, 1986). The difficulties
in developing long lasting immunity, including the mechanism
by which partial protection is finally achieved, remain largely
unexplained. Two main hypotheses, not mutually exclusive,
have been put forward (Greenwood and Targett, 2011). The
first suggests that adaptive immunity is especially challenged in
the case of P. falciparum malaria, as the key parasite protein
family, PfEMP1, has more than 60 variants (Gardner et al.,
2002). The second postulates that repeated exposure to malaria
antigens is needed to drive an effective immune response,
perhaps accompanied by a maturation of the immune system
with increasing age. Studying inflammatory cytokine responses
in individuals with malaria from areas of different transmission
intensities have shown that levels of pro-inflammatory cytokines
decreased with increasing transmission intensity (Ademolue
et al., 2017).
Origin, Spread, and Burden of Dengue
There is no consensus regarding the enzootic origin of dengue
virus (DENV); some suggest an African origin, others an Asian,
given the presence of sylvatic (“jungle”) viruses in both regions
(Rudnick et al., 1967; Gubler, 1987; Halstead, 1990). Irrespective,
the virus probably evolved into four distinct serotypes about
1,000 years ago within sylvatic cycles involving mosquitoes and
primates. Phylogenetic evidence suggests that each of the four
serotypes entered a cycle of stable transmission between humans
and mosquito vectors only 125–320 years ago, coinciding with
the out-of-Africa migration of the anthropophilic vector Aedes
aegypti (Crawford et al., 2017) and historical accounts of local
outbreaks and general pandemics of dengue-like disease from the
17th seventeenth century and onwards (Gubler, 1998; Twiddy
et al., 2003).
The global pattern of spread of the four dengue serotypes
since the early 1940s – when DENV was first isolated – has
been highlighted by Messina et al. (2014). These show consistent
dispersal of each serotype from South Asia over Southeast Asia
to the Pacific and the Americas, with relatively few reported
occurrences in sub-Saharan Africa, tribal areas of Papua New-
Guinea, North-East India and inner parts of South America. This
recently intensified transmission and spread of the DENVs is
largely attributed to massive urbanization and globalized travel
and trade that characterize the latter half of the 20th century.
Importantly, the urban ecology in the tropics has enabled the
proliferation of the “domestic” vector Ae. aegypti, while travel and
trade have helped widen the global range of both vector and virus
(Gubler, 1998; Li et al., 2014).
Today, an estimated 3.9 billion people live at risk of infection
in at least 128 countries (Brady et al., 2012). Dengue presents a
continuously expanding global disease burden, with a suggested
doubling or more in the number of symptomatic infections,
every 10 years – between 1990 and 2013 (Stanaway et al., 2016).
There is, however, wide variation and substantial uncertainty in
estimates of the dengue disease burden (Shepard et al., 2014)
given both under-recognition and under-reporting of dengue,
in general. Notably, only three WHO regions provide regular
reports of annual case numbers (WHO, 2017a). In 2015, WHO
recoded 3.2 million illness episodes (WHO, 2017a), yet the true
figure is probably far higher, with current estimates based on
comprehensive risk models ranging between 96 million (Bhatt
et al., 2013) in 2010 and 58.4 million in 2013 (Stanaway et al.,
2016).
Major challenges for understanding and controlling dengue
through the use of preventive or therapeutic interventions
include lack of a laboratory correlate and animal models to
investigate protective immunity; continued DENV evolution due
to major clade replacements and genetic shifts (Holmes and
Twiddy, 2003; Rico-Hesse, 2003; Endy, 2014); and not least the
complex viral-host pathogenesis that ranges from mild unspecific
manifestations to severe and potentially fatal disease (Endy,
2014). A tetravalent vaccine (Capeding et al., 2014; Hadinegoro
et al., 2015; Villar et al., 2015) has been licensed for use in several
endemic countries in South America and Asia. However, recent
data indicate increased risk of severe dengue among vaccinees
without previous exposure to DENV (WHO, 2017b) suggesting
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that – in spite of its tetravalent properties – the vaccine may
induce severe manifestations on secondary exposure, through
mechanisms of immuno-enhancement (Deen, 2016). Current
recommendations by the WHO/GACVS are that individuals who
have not been previously infected with wild DENV should not
be administered the vaccine (WHO, 2016, 2017b). In addition,
the long term effectiveness of this vaccine remains uncertain
(López-Gatell et al., 2016). As such, vector control remains
the principal dengue prevention option. The primary vectors
of DENV, Ae. aegypti and Aedes albopictus, are both diurnal,
rendering insecticide-treated nets of less use for dengue than
for malaria control. Public health efforts currently focus on
environmental management for elimination of vector breeding
sites and on various insecticide applications targeting either
larvae or adult stages in the peri-domestic environment (Chu
et al., 2013).
The Emergence of Severe Dengue as an
Epidemic Entity
The global emergence of severe DENV infection in the latter
half of the 20th century is closely aligned with the intensified
transmission and spread of the four serotypes, and the occurrence
of sequential transmission or actual co-circulation of two or
more serotypes (hyperendemicity) in a given population. Dengue
epidemics involving severe disease with mortality rates as high as
10% were first noted in Manila and Bangkok in 1954 (Hammon
et al., 1960; Hammon and Sather, 1964), but were soon followed
by similar epidemics in several other Southeast Asian cities
(Rudnick, 1967; Chambers et al., 1990; Endy, 2014). Urban
Southeast Asia remained the focus of intense epidemics of severe
dengue throughout the 1960s and 1970s, and by the 1970s
severe dengue was recorded as a leading cause of pediatric
hospitalization and death in many Southeast Asian countries
(WHO, 1997).
Whereas the Pacific islands experienced their first outbreaks
with severe dengue in the 1970s, the phenomenon was not
reported in the Americas before 1981, when Cuba reported a
large-scale epidemic with tens of thousands of severe dengue
cases (Guzman and Kouri, 2003). The subsequent pattern of
intensified transmission with frequent large-scale epidemics in
the urban centers of the Pacific and Americas has largely
mimicked that of Southeast Asia, albeit two to three decades
later. Thus, in the Americas, dengue has doubled every decade,
with increasing severity and mortality particularly in children
and young adults (San Martín et al., 2010). Interestingly,
Halstead et al. (2001) noted the absence of severe dengue despite
hyperendemic DENV transmission in Haiti.
For Sub-Saharan Africa, evidence of dengue disease – not least
that of severe disease – has been relatively sparse, even though the
disease is likely to have been present for centuries (Amarasinghe
et al., 2011). Notably, in 1970, Geser et al. (1970) reported the
presence of Ae. aegypti in the coastal area of Kenya. In addition,
47% of the population presented with hemagglutinin inhibiting
(HI) dengue antibodies, although no outbreaks of dengue had
been reported. In 1977, Fagbami et al. found that 45% of tested
adults in Nigeria were seropositive for anti-DENV-2 antibodies,
as evidenced by neutralizing antibodies (Fagbami et al., 1977).
In several African countries DENV transmission has been
recognized primarily through diagnosis of travelers or stationed
military personnel or through sero-prevalence population studies
(de Araújo Lobo et al., 2016; Onoja et al., 2016). It is mainly on
the basis of such evidence that dengue is considered endemic to
both East and West Africa (Brady et al., 2012).
Recent reviews have cataloged multiple small-scale outbreaks
of the 1980s and 1990s, across Sub-Saharan Africa (Messina et al.,
2014; Baba et al., 2016). Interestingly, the frequency and scale
of outbreaks appear to have increased – as have the numbers of
deaths – since the turn of this century (Massangaie et al., 2016).
Most notable are: the 2009 outbreak in Cape Verde, with 21,304
reported cases and four deaths; the 2010 outbreak in Sudan
involving 3,765 cases and 12 deaths; and the 2011 outbreak in
Kenya with 5,000 reported cases and four deaths (Baba et al.,
2016). Tanzania has experienced no less than four recurrent
outbreaks in 2010, 2012, 2013, and 2014, the latter of which
included more than 3,000 reported cases and four deaths (Mboera
et al., 2016) (Figure 1D).
It is generally argued that dengue and severe dengue have
been subject to under-diagnosis in Africa given a lack of index of
suspicion and little access to laboratory diagnostics (Amarasinghe
et al., 2011). However, awareness is typically high in this region
regarding hemorrhagic fevers and shock syndromes due to
the recurrent outbreaks of yellow fever, Lassa, Marburg, Ebola
and Crimean-Congo hemorrhagic fevers (Parkes-Ratanshi et al.,
2014). As such, one would expect that outbreaks involving severe
dengue would be subject to substantial levels of scrutiny. In
spite of the potential under-diagnosis of dengue, the apparent
escalation in dengue epidemic activity in Sub-Saharan Africa
(Stanaway et al., 2016) might suggest that the region is on the
verge of experiencing the emergence of severe dengue as an
epidemic entity, similar to the experience of South and Southeast
Asia in the 1950s, the Pacific in the 1970s, and the Americas in
the 1980s.
Risk Factors for Severe Dengue
Several factors have been shown to modulate the clinical response
to DENV infection. Notable risk factors for severe manifestations
include previous heterotypic DENV infection; viral virulence, co-
morbidities such as diabetes and hypertension; as well as host
genetic factors (Carabali et al., 2015; Halstead, 2015).
Immuno Pathogenesis
The groups of (Halstead, 1980, 1988, 2012), Rothman and
Ennis (1999), and Rothman et al. (2014) have both been
crucial in detailing different aspects of the immuno-pathological
mechanisms of severe disease that arise in response to
sequential heterotypic DENV infections. These mechanisms
implicate the development of heterotypic, cross-reactive but non-
neutralizing antibodies and T cells during primary infection
and their subsequent activation upon secondary infections
with a heterotypic serotype (Endy, 2014). Cross reactive IgG
DENV-antibodies have been shown (in vitro) to enhance viral
uptake and proliferation in target cells, a mechanism known
as antibody dependent enhancement (ADE) of infection with
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FIGURE 1 | Noted changes in malaria and dengue activity in Sub-Saharan Africa. (A,B) Estimated Plasmodium falciparum incidence (cases per 100,000) in 2000
and 2015. Modified from original MAP (Source: MAP, 2018). (C,D) Accumulated reports of dengue activity and reported dengue epidemics for the periods
1983–1999 and 2000–2015. (Source: Messina et al., 2014; Gideon, 2018).
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a second dengue serotype. Notably, recent studies suggest that
IgG DENV-antibodies may also be linked to thrombocytopenia
as observed in severe dengue (Wang et al., 2017). In addition,
cross reactive T-cells may unleash a cascade of cytokines and
chemical mediators linked to various severity outcomes including
endothelial permeability (Pang et al., 2007). New insights in the
immunopathology of dengue were recently reviewed by Screaton
et al. (2015).
A key point is that the risk of experiencing immune-mediated
pathogenesis increases if a population is subject to consecutive
infections by heterotypic serotypes. The emergence of severe
dengue throughout large parts of the world is thus aligned
with the increased global spread of each serotype. Co-circulation
of DENV types has been increasingly documented, even in
malarious areas of Sub-Saharan Africa (Messina et al., 2014).
Although the true extent of DENV co-circulation in Sub-Saharan
Africa remains unclear, it is notable that recent outbreaks,
as detailed above, have occurred predominantly in areas with
reported co-circulation of DENVs (Saluzzo et al., 1986; Caron
et al., 2013; Ridde et al., 2016).
Virulence
Rapid molecular evolution and genetic diversity is a common
feature among RNA viruses and may explain why certain strains
and genotypes of the four DENVs display greater epidemic
potential and pathogenicity than others. Gubler and Trent (1994)
were among the first to argue that increased circulation of DENVs
as observed in hyperendemic areas, increases the likelihood of
virulent strains, as viral competition intensifies the evolutionary
pressure on each serotype.
Co-morbidity With Other Than Malaria
A recent review of comorbidity with dengue identified –
in addition to old age – several non-communicable diseases
of importance for the development of severe manifestations
including: cardiovascular disease, diabetes, respiratory disease,
and renal disease (Toledo et al., 2016). However, due to
heterogeneity among studies, the real estimate effect of
comorbidities as modifiers of dengue severity could not
be established. Bacterial co-infection with dengue is also
increasingly described (Trunfio et al., 2017).
Host Genetic Factors
It has been reported that people of African descent are less
prone to suffer severe dengue than other ethnic groups, such as
Hispanics and Caucasians in Cuba (Guzman and Kouri, 2003),
Haiti (Halstead et al., 2001), Brazil (Blanton et al., 2008), and
Colombia (Palacios et al., 2016). This observation has offered
a plausible explanation for the absence of severe disease from
Sub-Saharan Africa – at least up until the recent outbreaks,
where severe dengue apparently has increased also among native
Africans, as indicated in the following. Furthermore, the study by
Moraes et al. (2013) did not confirm that Afro-Americans have
lower risks of severe dengue; on the contrary the risk was higher,
except when corrected for socio-economic risk factors. HLA and
other gene associations have also been linked with dengue disease
severity (Stephens, 2010).
EVIDENCE THAT ELIMINATION OF
FALCIPARUM MALARIA COINCIDES
WITH THE EMERGENCE OF SEVERE
DENGUE
In a review of the malaria elimination history, Tanner and
de Savigny (2008) noticed how regional malaria elimination
campaigns conducted in the late 1940s paved the way for the
Global Malaria Eradication Program in 1955. As part of this
campaign malaria was eliminated from Europe, North America,
the Caribbean (except Haiti) (Agarwal et al., 2012) and parts of
Asia and South and Central America during the 1960s and by the
early 1970s (Bruce-Chwatt, 1986).
After a temporary setback, in part due to the development
of insecticide- and drug-resistance, reduction of malaria by 50–
75% was eventually obtained in most of Asia and South and
Central America (WHO, 2013). However, no major success
was obtained in Sub-Saharan Africa until recent decades. As
indicated by Figures 1A,B, malaria is now on the retreat in
several parts of sub-Saharan Africa. Since 2000, a historically
unprecedented decline has been observed (Snow et al., 2017, the
Malaria Atlas Project - MAP). For example, malaria has virtually
disappeared even in children in Dar es Salaam, Tanzania (Strøm
et al., 2013). At the same time, major outbreaks of dengue have
been reported in Dar es Salaam, including the 2014 DENV2
outbreak registering a case fatality rate of 4% (Vairo et al., 2016).
Dengue epidemics have also been reported from other parts
of Tanzania (Mboera et al., 2016), neighboring Kenya (Brady
et al., 2012), Mozambique (Massangaie et al., 2016), as well
as Angola (Sharp et al., 2015), Sierra Leone (de Araújo Lobo
et al., 2016), Burkina Faso (Ridde et al., 2016), and Nigeria
(Onoja et al., 2016) and several other parts of Sub-Saharan
Africa (L’Azou et al., 2015). Notably, in 2017, dengue outbreaks
were reported from eight Sub-Saharan countries reaching an
excess of 21,000 total cases. Burkina Faso recorded more than
half of these cases (13,135) including 28 deaths (Gideon, 2018).
Details for accumulated reports of dengue including epidemic
activity in Sub-Saharan Africa from 1983 to 2015 are provided
in Figures 1B,C.
CO-MORBIDITY OF DENGUE AND
MALARIA
So far, we have discussed concurrent phenomena of dengue
emergence and malaria decline at population-level. Another
way to consider the hypothesis of mutual exclusion or
interdependence of the two pathogens comes from evidence
of co-infections at the patient-level. Clinical diagnosis and
distinction of malaria and dengue is difficult due to overlapping
symptoms. Either disease may induce similar general symptoms
as well as severe manifestations in terms of thrombocytopenia,
central nervous symptoms, “cytokine-storm” (Clark, 2007),
shock and even bleeding. Manifestations of concurrent infection
in a patient would be expected to have severe consequences (Hati
et al., 2012). However, as noticed by Mohapatra et al. (2012)
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reports on co-infection are relatively scarce in literature and those
of severe manifestations even more so.
The first patient with falciparum malaria and dengue co-
infection was reported by Charrel et al. (2005). Our own search
from 2005 to 2017 revealed 55 reports of co-infections, including
more than 360 cases of acute co-infections as confirmed by
malaria RDT and/or microcopy and DENV virology, antigen tests
and/or seroconversion (for details please refer to Supplementary
Material). The malaria-immune status was not reported for
most co-infections neither were parasitaemia levels which
could otherwise be used as a proxy for immunity (with high
parasitaemia indicating low immunity). Instead, we suggest that
malaria incidence in the countries from where co-infections were
reported may be used to assume the general level of malaria
immunity. With the exception of Sub-Saharan Africa, most areas
reported low or medium transmission of P. falciparum malaria
during the period of interest.
Table 1 includes only cases of P. falciparum in acute dengue
confirmed by DENV RT-PCR, NS1 test, or seroconversion. Of 74
identified co-infections, severe symptoms were only recorded in
three cases of which one was acquired in West Africa as reported
by Charrel et al. (2005). This case involved a traveler, assumed
to be non-malaria immune, who after returning to France
developed disseminated intravascular coagulation, which may be
a manifestation of either disease (ibid). Alam and Dm (2013)
reported a single case of cerebral malaria and dengue co-infection
in a military personnel located in Patna, India. Again, the level
of parasitaemia was not reported; however, cerebral malaria
would indicate low or absence of malaria immunity, in line
with the low incidence level reported for the area. Finally, Yong
et al. (2012) reported severe manifestations in a local Indonesian
adult male with 4% falciparum parasitaemia and dengue co-
infection. This case was complicated by rhabdomyolysis and
acute renal insufficiency, which may both be induced by malaria
and dengue.
Lack of reporting of dual infection in the field could result
from testing positive for either malaria or dengue infection with
no further testing being done, given low index of suspicion for
co-infections (i.e., case considered diagnosed after one positive
test). Yet, some argue that severity could also prompt testing
for dual disease, and thereby potentially bias reporting. Notably,
TABLE 1 | Reported cases of acute dengue virus and P. falciparum co-infections
by global region, 2005–2017.
Region Total
cases
Mild
symptoms
Severe
symptoms
Severity not
reported
Sub-Saharan Africa 5 1 11 3
Americas 28 7 0 21
South Asia 39 38 12 0
Southeast Asia 2 1 13 0
Total 74 47 3 24
Method of confirmation of acute dengue: RT-PCR, NS1 test and/or IgM/IgG
seroconversion. Categorization of severity based on case description by source
authors. Sources for severe cases: 1Charrel et al., 2005 (returning traveller); 2Alam
and Dm, 2013 (military personnel; 3Yong et al., 2012 (local resident). For additional
sources please refer to Supplementary Table 1).
studies that have actively investigated the clinical picture of
mono-infections as compared to that of dengue and malaria co-
infections disagree with respect to observed differences in severity
levels. Epelboin et al. (2012) reported that among local resident
in French Guyana, the clinical picture of dual infections was
more severe than in either dengue or malaria alone. It is notable
that P. vivax was identified in the majority of cases (∼80%) and
that only 50% of the dual infected reported previous malaria.
Unfortunately, the report did not stratify between P. vivax or
P. falciparum co-infections, nor did it report on parasitaemia
levels.
In contrast, Halsey et al. (2016) found similar severity
levels between mono and co-infected individuals among local
populations in Peru. As for Epelboin et al. (2012) the majority
of cases were reported as P. vivax. In India, Mohapatra et al.
(2012) reported generally benign manifestations among co-
infections as compared with malaria mono-infections. In this
study the majority of cases (∼90%) were reported as P. falciparum
infections. Notably, lower parasitic counts were observed among
co-infected than for mono-infected patient, although reported
as non-significant. In line with these findings, Ahmad reported
that the presentation and severity of co-infections appeared
“to be milder and outcomes comparable (if not better) to
mono-infections” during a dengue outbreak in Uttarakhand,
India. While co-infections occurred with both P. falciparum and
P. vivax these were not clearly distinguished in the report.
Stoler et al. (2015) reported dengue-specific IgG antibodies in
22% of urban Ghanaian children with P. falciparum parasitaemia,
suggesting previous exposure, and dengue IgM antibodies in
3%, indicating probable acute co-infection. While co-infection
was indicated, co-morbidity or increased severity was not.
None of the children appeared to have severe disease; but IgM
dengue positive children had (non-significantly) higher levels of
P. falciparum parasitaemia, which could indicate they were only
partially immune to falciparum malaria at the time of DENV
infection. Unfortunately, levels of malaria antibodies were not
reported. Specificity of the anti-dengue Ig tests used was 97% for
multisite pooled sera, though cross-reactivity with other flavivira
was high (30% and 60% for IgM and IgG, respectively).
Cross-Reactivity and “False-Positivity” in
Tests for Dengue and Malaria
Malaria infection gives rise to polyclonal B-cell activation
(Greenwood, 1974) and to heterophilic antibodies (Houba et al.,
1974), which may react to host antigens as well as to other
pathogens (Ribeiro, 1988). Some anti-dengue IgM tests have
shown a high degree of cross-reactivity (10–70%) with sera from
malaria patients, and with other flavivira (Hunsperger et al., 2009;
WHO, 2009). Hunsperger et al. (2009), when evaluating four
anti-DENV IgM kits and five micro-plate ELISAs found between
5 and 70% false-positive results for patients with malaria or past
dengue infections. Knowing the true population prevalence of
dengue as well as malaria infections is hampered by the lack
of representative population-based studies, and also by false-
positive test results or cross-reactivity that are a problem in many
serological assays including rapid diagnostic tests (RDTs) for
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dengue and malaria. In other words, a positive DENV IgM test
may signify current or recent primary infection, secondary or
tertiary infection (often lower titers, though primary infection
responses also vary), or cross-reactivity with other virus or
even malaria (current or past infection). Thus, with current
laboratory assays available in countries with limited resources,
it is very difficult to tease apart the possibility of malaria and
dengue together in an area or a patient, wherefore low-cost
antigen tests and viral and plasmodia gene detection kits are
needed.
Possible Co-protection of Malaria
Infection Against Severe Dengue?
Repeated exposure to falciparum malaria is followed by
development of protective antibodies, decline of pro-
inflammatory host-responses (Ademolue et al., 2017) and
decreasing severity (Reyburn et al., 2005), whereas sequential
exposure to heterogeneous DENVs – and related viruses, e.g.,
Zika virus – may lead to enhanced host immune responses
(Cohen, 2017). However, on the basis of the presented clinical,
epidemiological, immunological and laboratory-based reports,
we speculate whether cross-reactivity observed between tests for
dengue and malaria pathogens could also be an indicator of some
level of cross-protection between two potentially severe diseases.
In other words, could dengue-induced antibody-dependent
enhancement of infection (ADE) (de Alwis et al., 2014) be
“de-hanced” by malaria induced antibodies? Or could alleviated
cytokine responses among clinically malaria immune individuals
(Ademolue et al., 2017) similarly reduce “over”-reaction to
dengue (re-)infection?
Proof of concept of cross-protection from malaria to dengue in
man would require exposing malaria immune humans to dengue
in controlled experiments. As reviewed by Sabin (1952), research
on dengue during World War II did include research on human
volunteers exposed to DENV and the development of immunity
to the homologues strain. Unfortunately, the level of immunity to
malaria was not reported in these volunteers. A human model of
dengue exposure is currently being re-introduced (Larsen et al.,
2015; Royer, 2015).
Examples of Interspecies Interactions
In the literature, there are certainly important examples of
interaction between infections of unrelated pathogens leading
to more severe outcomes, such as HIV infection leading to
latent tuberculosis reactivation (Pitchenik et al., 1983), and
severe outcomes of pneumococcal disease following influenza
infection, the so-called lethal synergy (McCullers, 2014). And
most recently, Zika virus infection has been found to be enhanced
in recent dengue cases, much like ADE among the four DENV
types (Kawiecki and Christofferson, 2016). But examples in
which co- or sequential infection may decrease severity of either
or both diseases have been less investigated. An interesting,
historical example is the now obsolete treatment of syphilis
with malaria (Moore, 1930), and the possible sharp reduction
in tuberculosis in the US population immediately following the
1918 severe pandemic influenza outbreak (Noymer, 2011). More
recently, it has been shown that P. falciparum infection may
protect partly against severe Ebola outcomes (Rosenke et al.,
2016).
CONCLUSION
In summary, we conclude that at the population level the
evidence of interaction between dengue and malaria is perhaps
already there: when comparing time trends in the two diseases at
continent level, a suggestive pattern emerges. We have discussed
the striking coincidence of the emergence of dengue in recent
years (Figure 1D), with the reduction in incidence of malaria
(Figure 1B), suggesting that declining malaria exposure due to
successful control programs or other environmental factors may
have inadvertently led to the cessation of protection against
clinically apparent and severe dengue infections, especially in
Sub-Saharan Africa. However, individual-level studies would
be the best way to determine if co-protection exists between
falciparum malaria and dengue. Available individual-level studies
reviewed here are only suggestive and interpretation hampered
by non-specificity of used tests. Also, they present a risk of
bias in favor of our hypothesis, in that more severe patients are
more likely to be tested for several pathogens and subsequently
reported, and vice versa that lack of reporting of dual infection
in the field could result from testing positive for either
malaria or dengue infection and then no further testing being
done.
Evidently, more research is required to investigate whether
there is a causal link between declining falciparum malaria
and increased dengue in recent years. We suggest in vitro
experiments such as exposing in vitro cultures of DENV to
malaria antibodies, and vice versa as a proxy to evidence (or not)
of cross-protection. Other modern in vitro technologies including
epigenetic silencing or activation of regulatory genes implicated
in immunity and susceptibility of disease (Kirchner et al.,
2016) or development of animal models may also help, while
acknowledging that suitable animal models are still not available
for either infection. It would be interesting – if considered
ethically acceptable – to include malaria-immune individuals in
the ongoing dengue human exposure model. Further studies
of the potential role of unspecific sides of acquired immunity
(Muraille, 2016), and studies of cross-kingdom interaction
(Luckhart et al., 2015) could be rewarding as well. Especially,
if combined with integrated epidemiology and surveillance for
vector-borne diseases and by integrating layers of data from both
malaria and dengue (Wardrop, 2016). These studies could be
complemented by large-scale prospective studies e.g. through
the INDEPTH-network of health and demographic surveillance
systems in low- and middle-income countries (INDEPTH, 2018).
Finally, we believe it is important to broaden considerations
across pathogens and diseases in order to explain the striking
associations in temporal patterns of malaria and dengue globally
observed since the 1950s and in Africa, specifically, after the
Millennium. More broadly, we suggest that considering non-
specific effects of inter-species interaction and interdependences
may be a critical aspect of recognizing possible outcomes beyond
those of the target pathogen and to understand the broader
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consequences of global health intervention programs designed to
eliminate a given disease.
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